Status:
TERMINATED
Alcoholism and Schizophrenia: Effects of Clozapine
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Harvard Medical School (HMS and HSDM)
Conditions:
Schizophrenia
Dual Diagnosis
Eligibility:
All Genders
19-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have great...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or schizoaffective disorder
- Current diagnosis of an alcohol use disorder with active use in the last 30 days.
- The participant (or the participant's authorized legal representative) understands the nature of the study and has he/she signed an informed consent.
- Ages 19-65.
- Taking olanzapine, risperidone, quetiapine or a typical antipsychotic agent for at least 8 weeks prior to study randomization
- If taking depot medication, at least 3 injection cycles since the last injection prior to study randomization.
Exclusion
- Contraindication to clozapine
- Women who are currently pregnant or who desire to become pregnant during the course of the study.
- Current and past treatment with clozapine
- Current treatment with agents proposed to curtail substance use (e.g., disulfiram, naltrexone, acamprosate, buspirone) and agents contraindicated for use with clozapine (e.g., inderal, tegretol, lithium).
- Meets DSM-IV criteria for current dependence of substances other than alcohol.
Key Trial Info
Start Date :
May 1 1999
Trial Type :
INTERVENTIONAL
End Date :
January 1 2004
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00169026
Start Date
May 1 1999
End Date
January 1 2004
Last Update
March 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Commonwealth Research Center
Jamaica Plain, Massachusetts, United States, 02130